Adrenal insufficiency treated with conventional hydrocortisone leads to elevated levels of Interleukin-6: a pilot study
- 14 Downloads
Adrenal insufficiency is a rare disease with an estimated prevalence of 100–126 cases per million for primary adrenal insufficiency (PAI) and 450 cases per million for secondary/tertiary adrenal insufficiency (SAI/TAI) [1, 2]. Glucocorticoid replacement therapy (GRT) is the gold standard and only viable treatment for AI . The present guideline on PAI recommends the use of hydrocortisone (HC) or prednisolone for GRT . However, currently used GRT regimens inadequately mimic the physiological rhythm of endogenous cortisol secretion leading to temporary hypercortisolism and hypocortisolism . The consequences of these conditions are not completely understood but may be associated with deleterious effects on body composition . In fact, patients with AI on GRT have an increased cardiovascular and cerebrovascular mortality [6, 7].
Since inflammation is known to have a role in the pathogenesis of cardiovascular diseases, measurement of inflammatory markers has been suggested for...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.G. Mastorakos, G. Paltoglou, M. Greene, I. Ilias, A. Papamichalopoulos, S. Dimopoulos et al. Inappropriately normal plasma ACTH and cortisol concentrations in the face of increased circulating interleukin-6 concentration in exercise in patients with sarcoidosis. Stress 16, 202–210 (2013)CrossRefGoogle Scholar
- 9.D.A. Papanicolaou, C. Tsigos, E.H. Oldfield, G.P. Chrousos, Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J. Clin. Endocrinol. Metab. 81, 2303–2306 (1996)CrossRefGoogle Scholar
- 14.G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012)CrossRefGoogle Scholar
- 15.A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173–185 (2018)CrossRefGoogle Scholar